Cortagen

Cortagen (Ala-Glu-Asp-Pro; AEDP) is a synthetic tetrapeptide with the molecular formula C17H26N4O9 (molar mass 430.4 g/mol). It was derived by directed chemical synthesis from the amino acid composition of cortexin, a natural polypeptide extract of cattle cerebral cortex in clinical use in Russia since the 1980s, by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology.

The mechanism proposed by Khavinson and colleagues belongs to a broader "peptide bioregulation" framework. The core hypothesis is that the AEDP sequence has structural complementarity to specific DNA regulatory elements in cortical neurons, allowing the peptide to penetrate cell and nuclear membranes without surface receptor engagement and to act directly on gene promoter regions. This is proposed to produce tissue-specific modulation of transcription in a sequence-dependent manner.

The most experimentally supported component of this mechanism is epigenetic. A 2014 study in the International Journal of Peptide Research and Therapeutics found that Cortagen induced deheterochromatinization — decondensation of constitutively condensed heterochromatin — and reactivated ribosomal genes in aged human lymphocytes, an effect proposed to partially reverse age-related transcriptional silencing.

• Broad gene expression effects: A 2004 cDNA microarray study found that five consecutive days of Cortagen injection in female CBA mice produced statistically significant expression changes in 234 transcripts from 15,247 surveyed, corresponding to 110 known genes spanning signal transduction, stress response, and metabolic pathways.

• Tissue selectivity: A 2001 organotypic culture study found Cortagen selectively stimulated growth of rat brain cortex explants but not of liver, thymus, or subcortical tissue — supporting the organ-specific activity model.

It should be noted that direct DNA-binding by a small tetrapeptide has not been validated through standard independent molecular biology methods outside the Khavinson group.

All published research on Cortagen derives from a small number of studies conducted at Russian or post-Soviet institutions, predominantly from Khavinson's laboratory and close collaborators. No randomized controlled trials have been conducted in humans, no human pharmacokinetic data have been published, and no independent Western research group has replicated the principal findings. The entire evidence base is preclinical.

The best-characterized finding concerns peripheral nerve regeneration. Turchaninova and colleagues (Bulletin of Experimental Biology and Medicine, 2000; PMID 11276314) administered Cortagen intramuscularly at 10 mcg/kg once daily for 10 days to Wistar rats following sciatic nerve transsection and surgical suturing. Compared to untreated controls, treated animals showed a 27% increase in the growth rate of regenerating nerve fibers and a 40% increase in conduction velocity.

In a chronic cerebral ischemia model, Zarubina and Shabanov (Experimental and Clinical Pharmacology, 2011; PMID 21476278; article in Russian) reported that both Cortagen and the multi-peptide cortexin accelerated recovery of individual behavior in ischemic rats with varying hypoxia resistance, suppressed excess lipid peroxidation, and restored antioxidant activity in brain tissue, leading the authors to suggest potential utility in neuroprotective therapy.

A 2016 follow-up by the same group (Bulletin of Experimental Biology and Medicine 160(4):448-451; PMID 26902350; DOI 10.1007/s10517-016-3193-9) evaluated AEDP (Cortagen) in the context of ischemic preconditioning in rats, reporting reduced neurological deficit, restored behavioral structure, and antioxidant activity in both early and late preconditioning phases.

Adriani and colleagues at the Italian National Institute of Health (The Open Neuropsychopharmacology Journal, 2011; DOI 10.2174/1876523800902010022) tested Cortagen at 0.01, 0.03, and 0.10 mg/kg intraperitoneally in CD-1 mice using elevated-plus-maze and locomotor habituation paradigms. A dose of 0.03 mg/kg enhanced locomotion acutely and following five days of sub-chronic treatment, without notable effects on anxiety-related behavior. This represents the only published study from outside the Khavinson group.

Tissue selectivity in organotypic culture was demonstrated in 2001 (PMID 11713572), with Cortagen stimulating rat brain cortex explant growth but not explants from other organ types.

Typical dosage: 10 mg (daily for cycles).

No validated human dosage for Cortagen has been established through clinical trials. The following information derives from animal study parameters and extrapolations reported by the Khavinson group or described in community use; it should not be used to guide self-administration.

Animal study doses: • Sciatic nerve regeneration (rat, IM): 10 mcg/kg once daily for 10 days • Behavioral and locomotor effects (mouse, IP): 0.01 to 0.10 mg/kg; the 0.03 mg/kg dose produced motor stimulation with no adverse behavioral effects in the Adriani et al. study

Reported human research-context protocols (extrapolated from Khavinson group publications and described in Russian-language clinical summaries): • Subcutaneous injection: 1 to 10 mg per administration, once daily for 10 to 20 consecutive days • Courses are described as being repeated one to three times per year, typically in spring and autumn

Community/anecdotal use (not supported by clinical data): • Subcutaneous: 100 to 500 mcg per day for 10 to 20 days • Oral capsules (available from some Russian-market suppliers): 10 to 20 mg per day for 10 to 20 days; oral bioavailability has not been measured or published for this compound

No pharmacokinetic data (half-life, distribution, metabolism, or excretion) have been published for Cortagen in any species.

This information is provided for educational and reference purposes only and does not constitute medical advice. Cortagen is not approved for human therapeutic use by the FDA, EMA, or any comparable Western regulatory authority and is classified as a research compound.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

No peer-reviewed study has evaluated Cortagen in combination with any other compound. All combination use described below is anecdotal or based on practitioner extrapolation within the Khavinson bioregulator tradition.

Within the Russian peptide bioregulator framework, Cortagen is anecdotally combined with other organ-specific short peptides in multi-system "stack" protocols. The reported rationale is that each peptide targets a different organ, making co-administration additive rather than redundant:

• Epithalon (Ala-Glu-Asp-Gly): the pineal bioregulator, anecdotally paired with Cortagen on the basis that cerebrocortical and neuroendocrine aging are linked; Epithalon has its own separate preclinical literature. • Thymalin or Thymogen (thymic peptides): paired for immune support, on the hypothesis that immune and neurological aging are interconnected. • Pinealon (Glu-Asp-Arg): another short-peptide putative brain bioregulator, occasionally stacked for overlapping neuroprotective intent.

The 2004 microarray study compared gene expression profiles induced by Cortagen, Vilon, Epitalon, and melatonin in mouse heart and found both common and distinct genomic effects, suggesting these compounds are not pharmacologically interchangeable, but that study was not designed as a combination protocol.

No pharmacokinetic interaction data, additive or synergistic efficacy data, or safety data for any Cortagen combination exist.

Cortagen is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated

No formal human safety assessment of Cortagen has been published. The compound has not been evaluated in any registered human clinical trial, and pharmacovigilance data do not exist. Safety inferences can only be drawn from preclinical animal studies and anecdotal community reports.

In the published animal studies, no significant systemic toxicity was reported at doses used. The Adriani et al. (2011) mouse study, which tested Cortagen at 0.01 to 0.10 mg/kg intraperitoneally with both acute and five-day sub-chronic dosing, observed dose-dependent motor stimulation but no anxiogenic effects and no behavioral signs of adverse reaction. The ischemia and nerve regeneration studies from Zarubina and Khavinson's groups did not report adverse findings in rats.

The absence of adverse findings in animal studies should not be interpreted as established safety in humans. Several concerns remain unaddressed by published literature:

• Broad gene expression effects: The 2004 microarray study found that only five days of Cortagen injection altered expression of 110 known genes in cardiac tissue. The long-term consequences of repeated cyclic dosing on gene regulation across organ systems are unknown. • No pharmacokinetic characterization: Plasma half-life, protein binding, metabolic pathways, and excretion have not been reported. • No drug interaction data have been published. • No reproductive toxicity, genotoxicity, or carcinogenicity studies are available.

Anecdotal user reports most commonly describe mild and transient injection site reactions (erythema, soreness) and occasional fatigue early in a dosing course. These are consistent with non-specific responses to subcutaneous peptide injection rather than pharmacologically specific adverse effects.

Community precautionary contraindications include pregnancy, lactation, and use in children, reflecting prudent extrapolation in the absence of data rather than documented harm. Cortagen is a research compound and is not approved for human use in Western regulatory frameworks.